Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application

Minozzi et al., Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2020.06.015, Oct 2020
https://c19early.org/minozzi.html
Evaluation of the inter-rater reliability (IRR) and usability of the revised Cochrane risk of bias tool (RoB 2), showing low IRR, with Fleiss’ kappa values ranging from poor for overall judgment and certain domains, to moderate for the randomization process.
Minozzi et al., 31 Oct 2020, peer-reviewed, 5 authors.
DOI record: { "DOI": "10.1016/j.jclinepi.2020.06.015", "ISSN": [ "0895-4356" ], "URL": "http://dx.doi.org/10.1016/j.jclinepi.2020.06.015", "alternative-id": [ "S0895435620301815" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Clinical Epidemiology" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jclinepi.2020.06.015" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2020 Elsevier Inc. All rights reserved." } ], "author": [ { "affiliation": [], "family": "Minozzi", "given": "Silvia", "sequence": "first" }, { "affiliation": [], "family": "Cinquini", "given": "Michela", "sequence": "additional" }, { "affiliation": [], "family": "Gianola", "given": "Silvia", "sequence": "additional" }, { "affiliation": [], "family": "Gonzalez-Lorenzo", "given": "Marien", "sequence": "additional" }, { "affiliation": [], "family": "Banzi", "given": "Rita", "sequence": "additional" } ], "container-title": "Journal of Clinical Epidemiology", "container-title-short": "Journal of Clinical Epidemiology", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.jp", "clinicalkey.com", "jclinepi.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2020, 6, 18 ] ], "date-time": "2020-06-18T01:41:57Z", "timestamp": 1592444517000 }, "deposited": { "date-parts": [ [ 2020, 10, 21 ] ], "date-time": "2020-10-21T21:12:23Z", "timestamp": 1603314743000 }, "indexed": { "date-parts": [ [ 2025, 8, 12 ] ], "date-time": "2025-08-12T21:25:46Z", "timestamp": 1755033946600 }, "is-referenced-by-count": 273, "issued": { "date-parts": [ [ 2020, 10 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 1 ] ], "date-time": "2020-10-01T00:00:00Z", "timestamp": 1601510400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0895435620301815?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0895435620301815?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "37-44", "prefix": "10.1016", "published": { "date-parts": [ [ 2020, 10 ] ] }, "published-print": { "date-parts": [ [ 2020, 10 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1016/j.jclinepi.2010.04.026", "article-title": "GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables", "author": "Guyatt", "doi-asserted-by": "crossref", "first-page": "383", "journal-title": "J Clin Epidemiol", "key": "10.1016/j.jclinepi.2020.06.015_bib1", "volume": "64", "year": "2011" }, { "DOI": "10.1136/bmj.d5928", "article-title": "Cochrane bias methods group, Cochrane statistical methods group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", "author": "Higgins", "doi-asserted-by": "crossref", "first-page": "d5928", "journal-title": "BMJ", "key": "10.1016/j.jclinepi.2020.06.015_bib2", "volume": "343", "year": "2011" }, { "DOI": "10.1136/bmj.l4898", "article-title": "RoB 2: a revised tool for assessing risk of bias in randomised trials", "author": "Sterne", "doi-asserted-by": "crossref", "first-page": "l4898", "journal-title": "BMJ", "key": "10.1016/j.jclinepi.2020.06.015_bib3", "volume": "366", "year": "2019" }, { "DOI": "10.1136/bmj.i4919", "article-title": "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions", "author": "Sterne", "doi-asserted-by": "crossref", "first-page": "i4919", "journal-title": "BMJ", "key": "10.1016/j.jclinepi.2020.06.015_bib4", "volume": "355", "year": "2016" }, { "author": "Sterne", "key": "10.1016/j.jclinepi.2020.06.015_bib5" }, { "author": "Higgins", "key": "10.1016/j.jclinepi.2020.06.015_bib6", "series-title": "Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)", "year": "2019" }, { "DOI": "10.1016/j.jclinepi.2019.04.001", "article-title": "Risk of bias in non-randomised studies of interventions (ROBINS-I) showed low inter-rater reliability and challenges in its application", "author": "Minozzi", "doi-asserted-by": "crossref", "first-page": "28", "journal-title": "J Clin Epidemiol", "key": "10.1016/j.jclinepi.2020.06.015_bib7", "volume": "112", "year": "2019" }, { "DOI": "10.1007/s11336-007-9054-8", "article-title": "Variance estimation of nominal-Scale inter-rater reliability with random selection of raters", "author": "Gwet", "doi-asserted-by": "crossref", "first-page": "407", "journal-title": "Psychometrika", "key": "10.1016/j.jclinepi.2020.06.015_bib8", "volume": "73", "year": "2008" }, { "author": "Gwet", "key": "10.1016/j.jclinepi.2020.06.015_bib9", "series-title": "Handbook of inter-rater reliability", "year": "2010" }, { "DOI": "10.2307/2529310", "article-title": "The measurement of observer agreement for categorical data", "author": "Landis", "doi-asserted-by": "crossref", "first-page": "159", "journal-title": "Biometrics", "key": "10.1016/j.jclinepi.2020.06.015_bib11", "volume": "33", "year": "1977" }, { "DOI": "10.1136/bmj.l5221", "article-title": "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis", "author": "Naci", "doi-asserted-by": "crossref", "first-page": "l5221", "journal-title": "BMJ", "key": "10.1016/j.jclinepi.2020.06.015_bib12", "volume": "366", "year": "2019" }, { "DOI": "10.1016/0895-4356(90)90158-L", "article-title": "High agreement but low kappa: I. The problems of two paradoxes", "author": "Feinstein", "doi-asserted-by": "crossref", "first-page": "543", "journal-title": "J Clin Epidemiol", "key": "10.1016/j.jclinepi.2020.06.015_bib13", "volume": "43", "year": "1990" }, { "DOI": "10.1016/j.apmr.2018.12.036", "article-title": "Allocation concealment and intention-to-treat analysis do not influence the treatment effects of physical therapy interventions in low back Pain trials: a meta-epidemiologic study", "author": "de Almeida", "doi-asserted-by": "crossref", "first-page": "1359", "journal-title": "Arch Phys Med Rehabil", "key": "10.1016/j.jclinepi.2020.06.015_bib14", "volume": "100", "year": "2019" }, { "DOI": "10.1136/bmjopen-2015-008562", "article-title": "What is the influence of randomisation sequence generation and allocation concealment on treatment effects of physical therapy trials? A meta-epidemiological study", "author": "Armijo-Olivo", "doi-asserted-by": "crossref", "first-page": "e008562", "issue": "9", "journal-title": "BMJ Open", "key": "10.1016/j.jclinepi.2020.06.015_bib15", "volume": "5", "year": "2015" }, { "article-title": "Hernán MA Biases in randomized trials: a conversation between trialists and epidemiologists Epidemiology", "author": "Mansournia", "first-page": "54", "issue": "1", "key": "10.1016/j.jclinepi.2020.06.015_bib16", "volume": "28", "year": "2017" }, { "DOI": "10.1136/bmj.l6802", "article-title": "Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study", "author": "Moustgaard", "doi-asserted-by": "crossref", "first-page": "l6802", "journal-title": "BMJ", "key": "10.1016/j.jclinepi.2020.06.015_bib17", "volume": "368", "year": "2020" } ], "reference-count": 16, "references-count": 16, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0895435620301815" } }, "score": 1, "short-title": [], "source": "Crossref", "special_numbering": "C", "subject": [], "subtitle": [], "title": "The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "126" }
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit